Language Select
Varian Logo

Noticias recientes

Noviembre 20, 2017
At a ribbon-cutting ceremony involving company executives and government officials, Varian Medical Systems (NYSE: VAR) today announced the opening of its new facility in Jundiai, Brazil. One of... Read more
Noviembre 16, 2017
Varian Medical Systems (NYSE: VAR) today announced it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market in Japan the Varian Halcyon™ system,... Read more
Noviembre 14, 2017
Understanding the important role nurse navigators play in guiding cancer patients through their treatment process, Varian Medical Systems (NYSE: VAR) will be showcasing its new nurse navigation and survivorship solution November 16-19 in Orlando, FL at the AONN+ Navigation & Survivorship Conference, booth #609. This new solution is part of Varian’s 360 Oncology™, a web-based care management platform that integrates relevant health information so patients and their care teams can collaborate on the best care. Read more

Publicaciones recientes del blog

Oct 24, 2017 | Centerline
Doctors at the University Hospitals of Geneva (HUG) have begun to utilize the Calypso® GPS for the body® technology to enhance the accuracy of radiotherapy in the treatment of lung cancer.... Read more
Sep 20, 2017 | Blog Spot ON
Varian will be showcasing it's ProBeam® Proton Therapy System, configurable single-room and multi-room solutions with 360 degree gantries. Along with other several advanced technologies... Read more
Ago 30, 2017 | Centerline
Filippo Alongi, MD, director of radiation oncology at Sacro Cuore Don Calabria Cancer Care Center (Negrar-Verona, Italy), recently became the first clinician to use HyperArc™ high-definition... Read more

Corporate Communications Contacts

Corporate Communications Contacts

Corporate Communications Contacts

Mark Plungy
Director, Public Relations
650.424.5630
[email protected]

Mike Bruff
VP, Investor Relations
1 650 424 5163
[email protected]

Neil Madle
Director, Corporate Communications/Investor Relations, Europe
+44 (0)7786 526 068
[email protected]